Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Roche Holdings Ltd ADR (RHHBY)

Roche Holdings Ltd ADR (RHHBY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 297,429,824
  • Shares Outstanding, K 6,848,488
  • Annual Sales, $ 64,165 M
  • Annual Income, $ 13,585 M
  • 60-Month Beta 0.40
  • Price/Sales 4.80
  • Price/Cash Flow 13.57
  • Price/Book 8.22
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 04/22/20
  • Annual Dividend & Yield 0.72 (1.66%)
  • Most Recent Dividend 0.719 on 03/19/20
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate 1.40
  • Number of Estimates 1
  • High Estimate 1.40
  • Low Estimate 1.40
  • Prior Year N/A
  • Growth Rate Est. (year over year) -99.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
42.5500 +2.09%
on 05/27/20
45.8300 -5.21%
on 05/15/20
+0.6000 (+1.40%)
since 05/01/20
3-Month
35.0400 +23.97%
on 03/23/20
46.0000 -5.57%
on 04/28/20
+2.2400 (+5.44%)
since 03/02/20
52-Week
32.9500 +31.84%
on 06/03/19
46.0000 -5.57%
on 04/28/20
+10.5600 (+32.12%)
since 05/31/19

Most Recent Stories

More News
Ophthalmology Drugs And Devices Market Statistics 2019-2027: Share Forecasts, Trends & Growth drivers

Selbyville, Delaware Market Study Report adds 2019-2027 Global Ophthalmology Drugs And Devices report that offers an exhaustive coverage of the industry with brief analysis, data charts, figures, statistics...

AGN : 193.02 (+0.02%)
GSK : 41.69 (-0.38%)
RHHBY : 43.4500 (+0.05%)
SNPHF : 17.6500 (-2.19%)
VRX.TO : 30.80 (-3.33%)
Novartis' (NVS) Breast Cancer Drug Gets Positive CHMP Opinion

Novartis (NVS) gets positive CHMP opinion for breast cancer drug, Piqray. The company also announces other pipeline updates.

AZN : 54.31 (-1.54%)
RHHBY : 43.4500 (+0.05%)
MRK : 79.92 (+0.45%)
NVS : 86.07 (-0.70%)
Lilly's Cyramza Gets FDA Approval for First-Line Lung Cancer

FDA approves Lilly's (LLY) Cyramza as a combination regimen for metastatic EGFR-mutated non-small cell lung cancer. Cyramza is now approved for six indications to treat four different types of cancers....

AZN : 54.31 (-1.54%)
RHHBY : 43.4500 (+0.05%)
LLY : 151.74 (-0.47%)
ABBV : 90.85 (+0.17%)
The Zacks Analyst Blog Highlights: Merck, Glaxo, Roche, Sanofi and Bristol-Myers

The Zacks Analyst Blog Highlights: Merck, Glaxo, Roche, Sanofi and Bristol-Myers

SNY : 49.49 (-0.04%)
RHHBY : 43.4500 (+0.05%)
MRK : 79.92 (+0.45%)
GSK : 41.69 (-0.38%)
BMY : 59.92 (-0.61%)
Roche Starts Study on Actemra with Gilead's Drug for Coronavirus

Roche (RHHBY) commences a phase III study on Actemra with Gilead's remdesivir in hospitalized patients with severe COVID-19 pneumonia.

ALXN : 114.87 (-3.41%)
RHHBY : 43.4500 (+0.05%)
GILD : 73.33 (-2.43%)
INCY : 99.64 (-2.07%)
FDA Okays Lilly's Alzheimer's Disease Diagnostic Agent Tauvid

With the US regulatory agency's nod, Eli Lilly's (LLY) Tauvid became the first and the only approved radioactive diagnostic agent to image tau NFTs in the brain for effectively evaluating AD patients.

BIIB : 301.51 (+0.02%)
RHHBY : 43.4500 (+0.05%)
MRK : 79.92 (+0.45%)
LLY : 151.74 (-0.47%)
Pharma Stock Roundup: MRK, RHHBY Give Coronavirus Updates,SNY to Sell Stake in REGN

Merck (MRK), Glaxo (GSK) and Roche (RHHBY) make progress in coronavirus research efforts.

SNY : 49.49 (-0.04%)
AZN : 54.31 (-1.54%)
RHHBY : 43.4500 (+0.05%)
MRK : 79.92 (+0.45%)
LLY : 151.74 (-0.47%)
GSK : 41.69 (-0.38%)
BMY : 59.92 (-0.61%)
PhaseBio Gets FDA Nod to Begin Study for Coronavirus Treatment

PhaseBio (PHAS) receives clearance of IND application from the FDA to evaluate PB1046 as a treatment for hospitalized COVID-19 patients.

RHHBY : 43.4500 (+0.05%)
INCY : 99.64 (-2.07%)
NVS : 86.07 (-0.70%)
PHAS : 5.45 (-7.94%)
Mersana Stock Spikes on Interim Data on Cancer Candidate

Mersana's (MRSN) antibody-drug conjugate candidate, XMT-1536, achieves encouraging response rate in interim analysis of a phase I study in ovarian cancer patients.

RHHBY : 43.4500 (+0.05%)
AGEN : 4.14 (-2.36%)
AGTC : 4.80 (+0.42%)
MRSN : 20.23 (-4.44%)
Top Stock Reports for Alphabet, Visa & Bank of America

Top Stock Reports for Alphabet, Visa & Bank of America

V : 195.64 (+0.66%)
RHHBY : 43.4500 (+0.05%)
NVDA : 347.55 (-1.33%)
JPM : 99.42 (+0.83%)
GOOGL : 1,427.28 (-0.53%)
BAC : 25.00 (+1.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade RHHBY with:

Key Turning Points

2nd Resistance Point 43.6633
1st Resistance Point 43.5467
Last Price 43.4500
1st Support Level 43.3067
2nd Support Level 43.1833

See More

52-Week High 46.0000
Last Price 43.4500
Fibonacci 61.8% 41.0149
Fibonacci 50% 39.4750
Fibonacci 38.2% 37.9351
52-Week Low 32.9500

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar